The European Commission presented a Communication for the proposed launch of a European bio-defence preparedness programme called “HERA Incubator” to address the emerging threat of coronavirus variants.
Plans include important new research investments, mobilising an additional €30 million from Horizon 2020 to be complemented by a further €120 million from Horizon Europe.
The new programme will provide the means to detect and counter further coronavirus mutations and help ensure access to effective vaccines when a new virus or variant has emerged.
Horizon 2020 funding will support the rapid establishment of a new EU-wide vaccine trial network called VACCELERATE and boost capacities to track and analyse virus variants and to share data by reinforcing the European COVID-19 Data Platform and other existing research infrastructure projects and networks.
Horizon Europe funding will complement this action by providing further support for open data sharing, cohorts studies, and for vaccine trials.